In a move that caught even seasoned observers off guard, Donald Trump signed an executive order this week to accelerate psychedelic drug research and expand access, marking the most significant federal endorsement the emerging therapeutic market has received. The timing was surreal: the order came during Bicycle Day weekend, when users commemorate the first LSD trip, and Trump's folksy ad-libbing about ibogaine in the Oval Office underscored how far the conversation has shifted.
The practical impact is immediate. The FDA will fast-track three psychedelic drug applications that already hold breakthrough therapy designations, likely psilocybin treatments for depression and MDMA for post-traumatic stress disorder. The latter had been rejected by regulators in 2024. Psychedelic company stocks surged on the news.
"The expected issuance of these three vouchers shows just how much the White House has changed its mind on psychedelics in the last six months," said Josh Hardman, founder of Psychedelic Alpha, an industry analysis site. The shift signals a dramatic reversal from decades of federal prohibition, which began under Richard Nixon in 1970 as part of the broader war on drugs.
Beyond FDA expediting, the order makes investigational psychedelics including ibogaine available under "right to try" provisions, which permit terminally ill and treatment-resistant patients access to unapproved drugs. That provision immediately collides with DEA policy: the agency has maintained that schedule I substances are ineligible for such programs.
The Department of Health and Human Services announced a parallel $139 million initiative to support behavioral health therapies involving psychedelics, with at least $50 million earmarked to match state research projects. Veterans are a priority, reflecting growing evidence that ibogaine and psilocybin show promise for trauma-related conditions.
Yet the celebratory moment masks deeper tensions. Ismail Ali, co-director of the Multidisciplinary Association for Psychedelic Studies, a leading reform organization, cautioned against viewing the order as a wholesale victory. "Most people didn't have Trump accelerating psychedelic research on their bingo cards. It's so easy to be reductive about this. We really have to see both sides."
People continue to face criminal penalties for psychedelic offenses at state and federal levels, Ali noted, while pharmaceutical interests reap immediate benefits. "If you're looking at the US federal government for the full liberation of these plants, you're probably looking in the wrong place," he said. Still, he called it "a substantial threshold moment."
The Indigenous Question
A more troubling undercurrent runs through the initiative: the exploitation of Indigenous knowledge and resources. Sandor Iron Rope, former chair of the Native American Church of North America, described the order as "biopiracy dressed in clinical language." He warned that without explicit protections for Indigenous sovereignty, religious freedom, traditional knowledge, and equitable benefit-sharing, the psychedelic boom threatens to repeat a colonial pattern of extraction.
Ibogaine, a plant long used in West Africa and traditionally stewarded in Gabon, exemplifies the concern. When Americans for Ibogaine, represented in the Oval Office by CEO Bryan Hubbard, visited Gabon this year for the first International Conference on Iboga and Ibogaine, no agreements on royalties or profit-sharing were negotiated with traditional communities, according to reporting from Africa Coeur News.
The Gabonese sovereign wealth fund has signaled interest in controlling market access to ibogaine, which can be synthesized or extracted from other plants but originates from knowledge held in West African communities. Hubbard offered public gratitude to Gabon "for your stewardship of the sacred tree," but substantive protections remain absent from the executive order.
Regulatory hurdles also persist. The order directs rescheduling of psychedelics to accompany any FDA approvals, a process requiring DEA sign-off. Trump publicly urged his officials to accelerate the effort, saying they were "slow-walking" him. How that bureaucratic tug-of-war unfolds will determine whether the promise of psychedelic therapy reaches patients equitably or becomes another avenue for corporate and geopolitical consolidation.
Practitioners and researchers trained in underground and traditional settings face additional barriers. Jeffrey Singer, a surgeon at the Cato Institute, warned that the FDA pathway will likely restrict psychedelic therapy to licensed clinicians who often lack meaningful experience with these medicines, potentially sidelining decades of non-mainstream knowledge.
Author James Rodriguez: "Trump just handed the psychedelic movement the biggest federal win in fifty years, but the devil in the details suggests this is less about healing and more about who gets to profit and control the narrative."
Comments